News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
SAN DIEGO , July 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. ( Sandoz ), a Novartis division, today announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric
Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
SAN DIEGO , July 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. ( Sandoz ), a Novartis division, today announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric
Toggle Summary Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
SAN DIEGO , June 27, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaléo Inc. regarding kaléo’s claims of patent infringement relating to Adamis’ higher dose naloxone injection product (ZIMHI TM ), as well as, new claims
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
SAN DIEGO , June 27, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaléo Inc. regarding kaléo’s claims of patent infringement relating to Adamis’ higher dose naloxone injection product (ZIMHI TM ), as well as, new claims
Toggle Summary Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
SAN DIEGO , June 11, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration ( FDA ) has acknowledged the receipt of Adamis’ amendment to its previously submitted New Drug Application (NDA) for its higher dose naloxone
Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
SAN DIEGO , June 11, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration ( FDA ) has acknowledged the receipt of Adamis’ amendment to its previously submitted New Drug Application (NDA) for its higher dose naloxone
Toggle Summary Adamis Pharmaceuticals to Present at Conferences in June 2019
SAN DIEGO , May 29, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019.  During the conferences, management from Adamis will discuss the company’s business,
Adamis Pharmaceuticals to Present at Conferences in June 2019
SAN DIEGO , May 29, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019.  During the conferences, management from Adamis will discuss the company’s business,
Toggle Summary Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019 , it received notice that it had been named and served as a defendant in a lawsuit filed by kaléo Inc. in the United States District Court for the District of Delaware
Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019 , it received notice that it had been named and served as a defendant in a lawsuit filed by kaléo Inc. in the United States District Court for the District of Delaware
Toggle Summary Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration ( FDA ) of the proposed brand name for the company’s high dose naloxone product candidate.
Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration ( FDA ) of the proposed brand name for the company’s high dose naloxone product candidate.
Toggle Summary Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
SAN DIEGO , May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
SAN DIEGO , May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today that
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today that
Toggle Summary Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
SAN DIEGO , March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
SAN DIEGO , March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
SAN DIEGO --(BUSINESS WIRE)--Mar. 14, 2019-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
SAN DIEGO --(BUSINESS WIRE)--Mar. 14, 2019-- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment
Toggle Summary Adamis Provides Regulatory Update on Sublingual Tadalafil
SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration ( FDA ) regarding its New Drug Application (NDA) for its sublingual tadalafil product.
Adamis Provides Regulatory Update on Sublingual Tadalafil
SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration ( FDA ) regarding its New Drug Application (NDA) for its sublingual tadalafil product.
Toggle Summary Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that the article entitled “Higher doses of naloxone are needed in the synthetic opioid era” has been published in the peer reviewed journal Substance Abuse Treatment,
Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that the article entitled “Higher doses of naloxone are needed in the synthetic opioid era” has been published in the peer reviewed journal Substance Abuse Treatment,
Toggle Summary Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
SAN DIEGO , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. ( Sandoz ), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment
Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
SAN DIEGO , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. ( Sandoz ), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment